Natural products against acute respiratory infections: Strategies and lessons learned

Langeder, Julia; Grienke, Ulrike; Ya, Chen; Kirchmair, Johannes; Schmidtke, Michaela; Rollinger, Judith M.

doi:10.1016/j.jep.2019.112298

Cited by 39 publications

(33 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on clinical results, the General Office of the National Health, and the Office of the State Administration of Traditional Chinese Medicine encouraged the integration of herbal TCM and Western medicine in the treatment of respiratory complications in Coronavirus infections with different prescriptions recommended in different stages of disease ( Leung, 2007 ). After SARS-CoV-2 disease outbreak, a number of clinical trials with Traditional Herbal Medicines (THM) have been added to the body of evidence with some favorable findings when compared to standard antiviral therapy ( Langeder et al, 2020 ; Li et al, 2020 ; Luo et al, 2020 ; Rastogi et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

“…The rationale used in our study was to include, mostly, species known in the Americas and Europe and those already more widely available for the management of respiratory conditions ( Blumenthal, 2003 ; Edwards et al, 2015 ; Anheyer et al, 2018 ; Langeder et al, 2020 ), mainly regarding the symptoms (cough, pain, fever). We recognize that patients suffering from COVID-19 are likely to seek such herbal medications.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

et al. 2020

View full text Add to dashboard Cite

Background: Current recommendations for the self-management of SARS-Cov-2 disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case of high fever only. It is expected that many patients will add other symptomatic/adjuvant treatments, such as herbal medicines. Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally indicated for "respiratory diseases" within the current frame of the COVID-19 pandemic as an adjuvant treatment. Method: The plant selection was primarily based on species listed by the WHO and EMA, but some other herbal remedies were considered due to their widespread use in respiratory conditions. Preclinical and clinical data on their efficacy and safety were collected from authoritative sources. The target population were adults with early and mild flu symptoms without underlying conditions. These were evaluated according to a modified PrOACT-URL method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks balance of the treatments was classified as positive, promising, negative, and unknown. Results: A total of 39 herbal medicines were identified as very likely to appeal to the COVID-19 patient. According to our method, the benefits/risks assessment of the herbal medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea, Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we could not find compelling evidence to endorse the use of paracetamol and/or codeine. Conclusions: Our work suggests that several herbal medicines have safety margins superior to those of reference drugs and enough levels of evidence to start a clinical

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…China and Japan used this drug to diagnose and treat in uenza 52 . Favipiravir has not shown a binding effect under 100 µM 21 .…”

Section: Discussionmentioning

confidence: 99%

Molecular Docking Studies of SARS-Cov-2 Mainprotease Potential Inhibitors

Utami¹,

Fitriani

Aziz

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND : SARS-Cov-2 causes an coronavirus disease 2019 (COVID-19), and the vaccines or drugs of this disease have not been found to inhibit this replication of the virus. Researchers are engaged in all fields of study to discover new potential inhibitors. This study aimed to compute the binding energy (BE) and interactions between the new potential inhibitors and the SARS-Cov-2 Mainprotease (Mpro).METHODS: In this study, we docked between twenty-seven patented drugs and the Mpro receptor (PDB ID: 6W63). The molecular docking calculation was performed using AutoDock Tools 1.5.6. software. Moreover, the information about the biological activity of ligands was calculated using the PASS online server. The result of the calculation was then analyzed and visualized using Biovia Discovery Studio Visualizer. Further calculation, such as the ligand-protein interaction using STITCH database and Lipinski’s rule five were employed in this research.RESULTS: The molecular docking calculation results showed that nelfinavir was strongly bound to Mpro with BE of -9,51 kcal/mol, followed by lopinavir, vitamin D, ritonavir, and dexamethasone. From these ligands, we considered dexamethasone because this ligand works as an anti-inflammatory agent. CONCLUSIONS: Following the calculation, nelfinavir, lopinavir, and dexamethasone are proposed as a potential inhibitor of the Mpro receptor, but there is a need for further investigation.

show abstract

“…Viral pathogenesis is characterized as a number of distinct stages involving host–virus interactions, including attachment on cell surface, entry into cell through specific receptors, release of viral DNA/RNAs, viral genome replication and transcription, viral protein translation, virus assembly and repackaging, breakdown of host cell and triggering of host immune response et al ( Figure 1 ). A variety of natural products have been reported to possess potent antiviral activities in vitro and in vivo [ 1 •• , 2 , 5 , 8 , 9 , 10 ]. By surveying about 200 natural products with antiviral activity, we have selected 23 promising natural products with distinct antiviral mode of actions shown in Figure 1 .…”

Section: Antiviral Mode Of Actions Of Natural Productsmentioning

confidence: 99%

A roadmap to engineering antiviral natural products synthesis in microbes

2020

Current Opinion in Biotechnology

View full text Add to dashboard Cite

show abstract

Natural products against acute respiratory infections: Strategies and lessons learned

Cited by 39 publications

References 148 publications

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Molecular Docking Studies of SARS-Cov-2 Mainprotease Potential Inhibitors

A roadmap to engineering antiviral natural products synthesis in microbes

Contact Info

Product

Resources

About